G00002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

162162

(43) International publication date
17 July 2003 (17.07.2003)

PCT

(10) International publication number
WO 03/057697 A1

(51) International patent classification[7]:
C07D 471/08, A61K 31/439, A61P 25/00 // (C07D 471/08, 221:00, 209:00)

(21) International application number: PCT/FR03/00004

(22) International filing date: 3 January 2003 (03.01.2003)

(25) Language of filing: French

(26) Language of publication: French

(30) Data relating to the priority:
02/00,109 7 January 2002 (07.01.2002) FR

(71) Applicant (for all designated States except US): SANOFI-SYNTHELABO [FR/FR]; 174, avenue de France, F-75013 Paris (FR).

(72) Inventors; and
(75) Inventors/Applicants *(US only)*: GALLI, Frédéric [FR/FR]; 6, avenue de Rueil, F-92420 Vaucresson (FR). LECLERC, Odile [FR/FR]; 11, rue Winston Churchill, F-91300 Massy (FR). LOCHEAD, Alistair [GB/FR]; 95, rue de Paris, F-94220 Charenton le Pont (FR).

(74) Representative: LUDWIG, Jacques; Sanofi-Synthelabo, 174, avenue de France, F-75013 Paris (FR).

(81) Designated states *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated states *(regional)*: ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
- *With the International Search Report.*
- *Before expiry of the period provided for amending the claims, will be republished if such amendments are received.*


For an explanation of the two-letter codes and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.

As printed

(54) Title: DERIVATIVES OF 5-(PYRIDIN-3-YL)-1-AZABICYCLO[3.2.1]OCTANE, THE PREPARATION THEREOF AND THE APPLICATION OF SAME IN THERAPEUTICS

(54) Titre : DERIVES DE 5-(PYRIDIN-3-YL)-1-AZABICYCLO [3.2.1] OCTANE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

WO 03/057697 A1



(I)

(57) Abstract: The invention relates to compounds having general formula (I), wherein R denotes a halogen atom, a phenyl group which is substituted by one or more groups selected from among halogen atoms and the (C_1-C_6) alkyl, (C_1-C_6) alcoxy, nitro, amino, trifluoromethyl, cyano, hydroxy, acetyl or methylenedioxy groups, a pyridinyl group, a thienyl group, a indolyl group, or a pyrimidinyl group which is optionally substituted by one or more (C_1-C_6) alcoxy groups. Moreover, among the two carbon-carbon bonds denoted by ----, one is simple and the other can be simple or double. The inventive compounds are nicotinic receptor ligands.

(57) Abrégé : Composés répondant à la formule générale (I) dans laquelle R représente soit un atome d'halogène ou un groupe phényle substitué par un ou plusieurs groupes choisis parmi les atomes d'halogènes et les groupes (C_1-C_6)alkyle, (C_1-C_6)alcoxy, nitro, amino, trifluorométhyle, cyano, hydroxy, acétyle ou méthylènedioxy, soit un groupe pyridinyle, soit un groupe thiényle, soit un groupe indolyle, ou un groupe pyrimidinyle éventuellement substitué par par un ou plusieurs groupes (C_1-C_6)alcoxy, sachant que, parmi les deux liaisons carbone-carbone représentées par ----, l'une est simple et l'autre peut être simple ou double. Les composés de l'invention sont des ligands pour les récepteurs nicotiniques.